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OBJECTIVE: To determine if certain diagnoses and
comorbidities inﬂuence the risk of hospitalization for
angina patients. 
METHODS: Study was conducted using IMS HEALTH’s
LifeLinkTM database, a U.S. employer claims database 
consisting of more than 1.8 million covered lives, with
linked medical and pharmacy claims for employees, depen-
dents, and retirees from 1991 forward. Patients were diag-
nosed with angina in the period March 1, 1999 to
February 29, 2000. Unstable angina patients were placed
in a single cohort. Stable angina patients were further clas-
siﬁed based on the presence of hypertension, congestive
heart failure (CHF), diabetes, or other heart disease in the
36 months preceding their angina diagnosis.
RESULTS: 125,453 patients met the inclusion criteria—
32,672 with unstable angina and 92,781 with stable
angina. Patients with unstable angina were signiﬁcantly
more likely to be hospitalized (53.3%) than patients 
with stable angina (27.3%) (p < 0.001). When compar-
ing unstable to stable angina patients with comorbid con-
ditions, patients with unstable angina were more likely 
to be hospitalized than stable angina patients, regardless
of the combination of comorbidities in stable angina
patients (odds ratios between 1.20 and 10.47). Stable
angina patients with comorbid hypertension, diabetes,
and CHF had the most similar risk of hospitalization
compared to unstable angina patients, but still were sig-
niﬁcantly less likely to be hospitalized (OR = 0.83, 95%
CI = 0.79, 0.87). Unstable angina patients had the highest
likelihood of hospitalization compared to patients with
stable angina and no comorbidities (OR = 10.47, 95% CI
= 9.76, 11.22). Among stable angina patients, hospital-
ization rates were highest for patients with comorbid
CHF (ranging from 36.6% for patients with CHF only 
to 48.7% for patients with CHF, hypertension, and 
diabetes).
CONCLUSIONS: Patients with unstable angina were 
signiﬁcantly more likely than stable angina patients to 
be hospitalized, even if the stable angina patients had a
number of complicating comorbid conditions. Presence 
of unstable angina greatly increased the risk of 
hospitalization.
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ECONOMIC EVALUATION OF THREE MARKET
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The National Institutes of Health’s Adult Treatment Panel
III (ATP-III) guidelines deﬁne the population of hyperc-
holesterolemic patients for whom drug therapy is sug-
gested. A wide body of evidence indicates that elevated
low-density lipoprotein (LDL-C) is a major risk factor for
coronary heart disease (CHD). Thus, the ATP-III guide-
lines target LDL-C levels for reduction in hypercholes-
terolemic patients in an effort to reduce CHD risk. The
drug of choice is an HMG-CoA Reductase Inhibitor
(statin), which has demonstrated effectiveness in reducing
LDL-C.
OBJECTIVES: To determine if the relative cost-
effectiveness of the three most commonly prescribed
statins is affected by the initial LDL-C and ATP-III goals. 
METHODS: A Monte Carlo simulation was used to
model therapeutic course to target using data from pub-
lished trials including (pre-treatment LDL-C distribu-
tions, expected LDL-C reduction by drug and dose and
ATP-III LDL-C goals). Data from this model were entered
into a cost-effectiveness analysis model in Data 4.0
(TreeAge Software, Inc, 2001). One-way sensitivity 
analyses were conducted upon pre-treatment LDL-C 
distribution, statin performance, and costs of: drugs, 
time away from work/home, ofﬁce visits, laboratory tests
and mono-therapy failure.
RESULTS: Atorvastatin dominated the model, having 
the lowest drug cost and failure rate, regardless of initial
LDL-C level or ATP-III guideline goal. Base case (mean
LDL-C 188.9mg/dl [SD 24.0] and goal LDL-C of 
100mg/dl) cost-effectiveness ratios for atorvastatin, sim-
vastatin and pravastatin were $(US) 1,721, $(US) 3,641
and $(US) 22,029 respectively. Alternative case (mean
LDL-C 149.6mg/dl [SD 16.8] and goal LDL-C of 100
mg/dl) cost-effectiveness ratios for atorvastatin, simvas-
tatin and pravastatin were $(US) 965, $(US) 1,552 and
$(US) 2,498 respectively.
CONCLUSIONS: Atorvastatin was the most cost-
effective treatment among the tested statins. Cost-
effectiveness rankings were insensitive to all tested vari-
ables. Cost-effectiveness was primarily determined by the
performance characteristics of each drug and drug cost.
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It is well known that surgery performed under general
anesthesia commonly results in hypothermia. Surgical
hypothermia is a serious, but preventable, condition. 
It is becoming increasingly important, however, to
provide decision-makers with evidence of the cost-
effectiveness as well as the clinical beneﬁt of preventive
measures.
OBJECTIVE: Using the hospital perspective, the out-
comes and cost-effectiveness of the Arctic Sun Model 
100 for the prevention of hypothermia in patients under-
going off-pump coronary artery bypass surgery is
explored. 
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METHODS: Data for the cost-effectiveness analyses were
obtained from a case control study and two randomized
controlled trials comparing the surgical outcomes related
to temperature control using the Arctic Sun versus the
current surgical warming methods. The incremental cost-
effectiveness per hypothermia case avoided was calcu-
lated by measuring the extra costs to the hospital for
achieving an extra unit of effectiveness by using the Arctic
Sun.
RESULTS: Using the deﬁnition of hypothermia as a 
temperature less than 36°C, there were three cases (5%)
of post-operative hypothermia out of 58 for patients
warmed using the Arctic Sun method. Using the standard
of care, 23 out of 48 patients (48%) were hypothermic.
The treatment costs for preventing post-operative
hypothermia includes $60 in variable costs for the stan-
dard of care. Costs for using the Arctic Sun for prevent-
ing post-operative hypothermia included $350 in variable
costs and $9.85 in allocated annual ﬁxed costs (total
treatment cost—$359.85 per patient). Subtracting the rel-
ative cost to treat 100 patients using the standard of care
($6,000) from the relative cost of warming 100 patients
using the Arctic Sun ($35,985) yielded an incremental
cost effectiveness of $697.33 per post-operative hypother-
mia case avoided by using the Arctic Sun. 
CONCLUSION: Use of the Arctic SunTM is both effective
and cost-effective in preventing post-operative hypother-
mia during OPCAB procedures.
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Approximately 1.5 million individuals experience a
myocardial infarction (MI) each year in the United States.
Of these, 20% develop major depression (MDD) and are
at increased risk of re-infarction, overall morbidity and
mortality.
OBJECTIVE: The objective of this study was to compare
the health care costs and resource utilization for patients
diagnosed with MI + MDD with patients with MI only,
MDD only and a control group having neither condition. 
METHODS: Claims data for all patients at least 40 years
of age from a large HMO in the Southeast US were ana-
lyzed retrospectively. Patients were selected for study if
they had an incident event of MI, MDD, or MI+MDD
during a one-year recruitment period. Age and sex
matched patients having neither MI nor MDD during the
recruitment period served as the control group. Patients
were followed for two years from their dates of recruit-
ment. Patients were included in the MI+MDD group only
if they had at least six months of data for analysis. Only
patients with drug charges were included for ﬁnal 
evaluation.
RESULTS: Compared with $6,877 for patients in the
control group (n = 436), mean total costs were statisti-
cally different for each group, including $13,982 for
MDD patients (n = 296), $35,589 for MI patients (n =
98), and $57,835 for MI+MDD patients (n = 53). Signif-
icant differences between the groups were found for the
number of hospitalizations, length of hospital stay, out-
patient visits, types of prescribed medication, and number
of ﬁlled prescriptions. Other signiﬁcant differences be-
tween groups included their need for therapeutic drug
assays, particularly digoxin, and cardiovascular labora-
tory procedures, particularly the use of devices to monitor
for arrhythmia. 
CONCLUSION: The cost of illness and resource utiliza-
tion for patients who had MI+MDD are much greater
than patients having MI or MDD alone. Early recogni-
tion of patients with MI+MDD is warranted.
CARDIOVASCULAR DISEASES/DISORDERS—
Quality of Life Presentations
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Validity and clinical relevance of the quality of life (QL)
measures developed in Western civilization societies may
quite differ from those in countries experiencing socioe-
conomic hardships.
OBJECTIVES: We aimed to validate the set of QL ques-
tionnaires in essential hypertensives (EH) from Belarusian
population. 
METHODS: Internationally recognized, self-
administered, culturally non-speciﬁc, and professionally
translated into Russian questionnaires were used: the
General Well-Being Adjustment Scale (GWBAS), Duke
Health Proﬁle (DHP), Giessen Somatic Complaints Ques-
tionnaire (GSCQ). The QL assessment was carried out in
212 EH without concomitant diseases (100 males; mean
age 48.5 ± 12.3 years; BMI 30.3 ± 13.3kg/m2; SBP 168.4
± 26.6mmHg, DBP 105.4 ± 13.3mmHg) and in 57 
age-, gender- and BMI-matched healthy subjects.
RESULTS: Cronbach’s coefﬁcient alpha more then 0.7
was determined for GWBAS subscales (range 0.67–0.84;
mean 0.77) excepting “self-control”, for GSCQ (range
0.54–0.86; mean 0.74) excepting “gastric complains”,
but not for DHP (range 0.47–0.68; mean 0.57). Correla-
tion matrix revealed signiﬁcant and the highest Spearmen
correlation coefﬁcients of GWBAS subscales scores with
corresponding DHP and GSCQ subscales scores, except-
ing GWBAS subscale “vitality”. The total well-being
